Liver metabolomic investigation of lentiviral targeting of GDPD5 and GDPD6 for breast cancer treatment in a preclinical model

High-resolution ¹H MRS is a powerful technique for metabolomics studies of tissues, cells, and body fluids. Here we have used this technique to explore metabolomic changes in the livers of mice that have been treated with lentiviral particles that silence either of the two glycerophosphodiesterase GDPD5 (GDPD5-shRNA) or GDPD6 (GDPD6-shRNA). We systemically administered lentiviral shRNA in mice with orthotopic breast tumor xenografts. We identified distinct increases in leucine, valine, glutathione, creatine, glucose, tyrosine, and histidine in the GDPD5-shRNA treated group, whereas cholesterol, isoleucine, beta-hydroxy butyrate, alanine, glutamate, glutamine, aspartate, fumerate, phenylalanine, and formate were elevated in the GDPD6-shRNA treated group.